Cardiovascular Risk in Prostate Cancer

This publication has 39 references indexed in Scilit:

• Survival in Patients With De Novo Metastatic Prostate Cancer
  JAMA Network Open, 2024
• Survival Trend in Individuals With De Novo Metastatic Prostate Cancer After the Introduction of Doublet Therapy
  JAMA Network Open, 2023
• Cause of death during prostate cancer survivorship: A contemporary, US population–based analysis
  Cancer, 2021
• Assessment and Management of Cardiovascular Risk Factors Among US Veterans With Prostate Cancer
  JAMA Network Open, 2021
• Risk of developing hypertension after hormone therapy for prostate cancer: a nationwide propensity score-matched longitudinal cohort study
  International Journal of Clinical Pharmacy, 2020
• A Prospective Study of the Association between Physical Activity and Risk of Prostate Cancer Defined by Clinical Features and TMPRSS2:ERG
  European Urology, 2019
• Quantifying Observational Evidence for Risk of Fatal and Nonfatal Cardiovascular Disease Following Androgen Deprivation Therapy for Prostate Cancer: A Meta-analysis
  European Urology, 2015
• Cardiovascular Morbidity Associated with Gonadotropin Releasing Hormone Agonists and an Antagonist
  European Urology, 2014
• Association of Androgen Deprivation Therapy With Cardiovascular Death in Patients With Prostate Cancer
  JAMA, 2011
• Metabolic changes during gonadotropin‐releasing hormone agonist therapy for prostate cancer
  Cancer, 2008